Cannabis Pharmacology

Does cannabis always get you high? Is it safe for everyone? This is our perspective as pharmacologists.

References:
1. U.S. Food and Drug Administration. Drugs@FDA: Marinol. Available at: https://www.accessdata.fda.gov/script.... (Accessed: 17th July 2017)

2. Cross, J. H. et al. Cannabidiol (CBD) Significantly Reduces Convulsive Seizure Frequency in Dravet Syndrome (DS): Results of a Multi-center, Randomized, Double-blind, Placebo-controlled Trial. Neurology (2017).

3. Devinsky, O. et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 15, 270–278 (2016).

4. Thiele, E. et al. Cannabidiol (CBD) Significantly Reduces Drop Seizure Frequency in Lennox-Gastaut Syndrome (LGS): Results of a Multi-center, Randomized, Double-blind, Placebo-controlled Trial. (2016).

5. Wong, M. et al. A Dose Ranging Safety and Pharmacokinetic Study of Cannabidiol (CBD) in Children With Dravet Syndrome. (2016).

6. Russo, E. B. & al., et. Cannabidiol Claims and Misconceptions. Trends Pharmacol. Sci. 38, 198–201 (2017).

7. Elphick, M. R. & Egertová, M. The neurobiology and evolution of cannabinoid signalling. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356, 381–408 (2001).

8. Carney, R., Cotter, J., Firth, J., Bradshaw, T. & Yung, A. R. Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta-analysis. Acta Psychiatr. Scand. 136, 5–15 (2017).

9. Di Forti, M. et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr. Bull. 40, 1509–17 (2014).

10. Large, M., Sharma, S., Compton, M. T., Slade, T. & Nielssen, O. Cannabis Use and Earlier Onset of Psychosis. Arch. Gen. Psychiatry 68, 555 (2011).

11. Dragt, S. et al. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr. Scand. 125, 45–53 (2012).

12. Iseger, T. A. & Bossong, M. G. A systematic review of the antipsychotic properties of cannabidiol in humans. (2015). doi:10.1016/j.schres.2015.01.033

13. Crippa, J. A. S. et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 25, 121–130 (2011).

14. Zuardi, A. W. et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr. Pharm. Des. 18, 5131–40 (2012).

15. Thomas, A. et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150, 613–623 (2009).

16. Bhattacharyya, S. et al. Induction of Psychosis byΔ9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing. Arch. Gen. Psychiatry 69, 27 (2012).

17. ElSohly, M. A. et al. Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States. Biol. Psychiatry 79, 613–9 (2016).

18. Jikomes, N. & Zoorob, M. The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products. Sci. Rep. 8, 4519 (2018).

19. Kedzior, K. K. & Laeber, L. T. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies. BMC Psychiatry 14, 136 (2014).